| HCTZ fixed-dose combination therapy | ||
---|---|---|---|
Outcome measures | ARB/HCTZ | ACEI/HCTZ | BB/HCTZ |
Persistence (Odds Ratio, 95% CI) | 0.369a (0.356, 0.383) | 0.380a (0.368, 0.393) | 0.382a (0.370, 0.395) |
Adherence (Odds Ratio, 95% CI) | 0.457a (0.440, 0.475) | 0.495a (0.478, 0.513) | 0.398a (0.385, 0.412) |
PDC at end of follow-up period (Odds Ratio, 95% CI) | 0.388a (0.374, 0.403) | 0.415a (0.402, 0.429) | 0.435a (0.421, 0.449) |
MPR (HCTZ vs. fixed-dose) | 44.4 vs 61.0 Δ = -16.6b | 44.6 vs 57.5 Δ = -12.9b | 44.5 vs 61.5 Δ = -17.0b |